Drug Approved for Three Types of Leishmaniasis — Physician’s First Watch
Drug Approved for Three Types of Leishmaniasis
By Kristin J. Kelley
The alkyllysophospholipid miltefosine (Impavido) has been approved to treat visceral, cutaneous, and mucosal leishmaniasis in patients 12 years and older. The oral drug is the first approved for types of the disease — which is found in tropical regions and is transmitted by sand fly bites — that affect the skin and the nose and throat.